Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes
NEWTOWN, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced one oral and one poster presentation at the 14th International Symposium on Myelodysplastic Syndromes taking place May 3-6, 2017 at the Palacios de Congresos de Valencia in Valencia, Spain. These presentations will be made by the Company's collaborators from the Mount Sinai School of Medicine and the Cleveland Clinic.
Date: May 4th through May 6th
Time: 8:00 am
Location: Poster Presentation Section
Presenter: Dr. Aziz Nazha - Cleveland Clinic, Cleveland, Ohio
A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in Myelodysplastic Syndromes (MDS) Patients Treated with Rigosertib versus Best Supportive Care (BSC) in a Randomized Controlled Phase III trial
Date: Saturday May 6th
Time: 8:30 am-10 am
Location: Auditorium 1
Presenter: Dr. Shyamala Navada - Mount Sinai School of Medicine, NYC
Combination of Oral Rigosertib and Injectable Azacitidine In Patients with Myelodysplastic Syndromes (MDS)
Additional details and content from these presentations will be available on the Company's website on the day of the presentations.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule agent, which blocks cellular signaling by targeting RAS effector pathways. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials with Onconova's lead compound, rigosertib, are aimed at unmet medical needs of patients with MDS. For more information, please visit http://www.onconova.com .
GENERAL CONTACT: http://www.onconova.com/contact/ INVESTOR RELATIONS CONTACT: Lisa Sher, MBS Value Partners on behalf of Onconova Therapeutics Lisa.Sher@mbsvalue.com / (212) 750-5800
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
Mitratech24.9.2018 16:02 | pressemeddelelse
Mitratech Launches Latest TeamConnect ELM Innovations at Interact
Seclore24.9.2018 15:01 | pressemeddelelse
Seclore Offers the First Open Data-Centric Security Platform
XBiotech Inc.24.9.2018 14:32 | pressemeddelelse
XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa
IASLC24.9.2018 01:02 | pressemeddelelse
Researchers, Survivors, Advocates and Physicians Convene to Discuss Innovations in Lung Cancer Research, Treatment and Advocacy at the Largest-Attended World Conference on Lung Cancer
Oasmia Pharmaceutical AB21.9.2018 13:22 | pressemeddelelse
Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European Union
Patton Electronics Co.20.9.2018 22:17 | pressemeddelelse
Service Providers Speed Deployment, Reduce Costs with Patton Cloud Edge Orchestration Service
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum